Management of uterine fibroids
DOI:
https://doi.org/10.47464/MetroCiencia/vol31/2/2023/92-95Keywords:
fibroids, leiomyomas, fibromyomasAbstract
Uterine fibroids, also known as leiomyomas or fibromyomas, are the most common benign solid tumors in the uterus. Their prevalence has been underestimated since studies focus on symptomatic women; it varies depending on the region, country, diagnostic method and the population studied, between 5% to 60% of women have fibroids, and 30% of these produce symptoms such as abnormal uterine bleeding, pelvic pain or a sensation of pelvic heaviness1.
Downloads
References
Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. International Federation of Gynecology and Obstetrics. 2020;: p. 3 - 9.
Donnez J, Dolmans Mm Uterine fibroid management: from the present to the future. Human Reproduction Update. 2016;: p. 1-22.
Islam S, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Human Reproduction Update. 2018 Noviembre; 24(1).
Stewar EA, Adelman MR, Jacoby VL. ACOG PRACTICE BULLETIN. Management of Symptomatic Uterine. The American College of Obstetricians. 2021 Junio; 137(6).
El Sabeh M, Borahay MA. The Future of Uterine Fibroid Management: a More Preventive and Personalized Paradigm. Society for Reproductive Investigation. 2021 Mayo.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Alejandro Merino
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
